OBJECTIVE: To develop and employ a structure-based design rationale for the engineering of the zinc binding site of carbonic anhydrase II (CAII); this work is leading to the development and deployment of a metal ion biosensor. This AASERT award complements the research effort funded by the main ONR grant, "Structural Studies of Metalloprotein Design".
APPROACH: Site-specific mutagenesis experiments in the laboratory of collaborator Carol Fierke (Duke University) are guided by molecular modeling experiments with the goal of predicting structure-stability relationships in engineered metal site variants of CAII. To provide proof-of-concept in the design-analysis-redesign cycle, variants are subsequently subject to high resolution X-ray structure determination.
ACCOMPLISHMENTS: The structures of 30 CAII variants relevant to the design of a CAII-based biosensor have been determined. We have determined the most detailed structure-affinity relationships known for any zinc metalloenzyme. Our work has focused on (a) direct metal ligands, (b) indirect metal ligands (i.e., those that accept hydrogen bonds from direct metal ligands), and (c) hydrophobic residues that surround , . the protein-zinc binding site. Highlights of this work r " include the structure-based engineering of the tightest *Q protein-zinc binding site: the T199C variants exhibits ^*^ femtomolar zinc affinity. Additionally, we are now capable £Q of engineering protein-metal affinity by factors of 10 from _~ the micromolar range to the femtomolar range. >D Substitution of direct metal ligands H94, H96, and H119 by ^~ negatively-charged cysteine, aspartate, and glutamate ££ residues typically maintains the tetrahedral zinc j-, coordination polyhedron, including the zinc-bound solvent ^^ molecule. However, these variants usually exhibit ?C\ compromised affinity and catalytic activity, and the pKa ^& value for zinc-bound solvent is dramatically increased. This f*} is due to the perturbation of the electrostatic environment ^^ of the metal ion. Introduction of a new negative charge from »** the protein compromises the ability of the metal ion to ^* stabilize bound hydroxide ion, which results in an elevated . .
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pKa value. Accordingly, introduction of neutral asparagine and glutamine ligands in place of H119 results in CAII variants that retain substantial catalytic activity and exhibit near-normal pKa values for zinc-bound solvent.
Substitution of indirect zinc ligands results in more subtle effects on structure-affinity relationships. The carboxamide side chain of Q92 accepts a hydrogen bond from zinc ligand H94. The structure of the Q92E variants reveals an essentially isosteric replacement of the carboxamide side chain by the carboxylate side chain. However, the pKa of zinc-bound solvent is slightly elevated, due to the perturbation of the electrostatic environment of the metal ion. The introduction of a new negative charge even one residue removed from the metal ion affects the biological role of the metal ion in stabilizing its bound hydroxide don.
Iri an unusually dramatic example, the isosteric E117Q substitution results in severely-compromised activity (E117 accepts a hydrogen bond from zinc ligand H119). Unexpectedly, the structure of the E117Q variant suggests that this substitution stabilizes H119 as the negativelycharged histidinate anion, reflected by the corresponding increase in the pKa value for zinc-bound solvent.
Recent studies have focused on multiple-site CAII variants with amino acid substitutions in the beta-strand containing metal ligands H94 and H96. Structural comparison of the metal-bound and metal-free forms of selected double-and triple-site variants reveal conformational changes upon metal binding that are responsible for altered and more favorable metal binding kinetics. These CAII variants in particular are well-suited for application in a real-time CAII-based zinc biosensor, and work to this end is continuing in the laboratories of Carol Fierke (Duke University) and Richard Thompson (University of Maryland).
SIGNIFICANCE: Our structure-based redesign experiments with CAII yield valuable information regarding structure-stability relationships of zinc binding sites in proteins. Our collaborators Carol Fierke (Duke University) and Richard Thompson (University of Maryland School of Medicine) are now exploiting this information to optimize the molecular properties of the CAII-based biosensor.
PATENT INFORMATION: A patent application has been filed jointly with Richard Thompson at the University of Maryland on the use of CAII as a metal ion biosensor using a fluorescence anisotropy sensing scheme.
AWARD INFORMATION: Pfizer Award in Enzyme Chemistry from the American Chemical Society, 1999.
